~~<i id='A18D5449CD'><strike id='A18D5449CD'><tt id='A18D5449CD'><pre id='A18D5449CD'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：explore 2025-09-12 22:15:35 Page View：296

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Beam, Prozac, "TechBio" and more
Next article： Peter Hotez and the public health issue of online harassment

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

What we’ve learned from the Aduhelm mess

MollyFergusonforSTATSTATnowpublishesselectedLetterstotheEditorreceivedinresponsetoFirstOpinionessays

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

AdobeLastweek,theWashingtonPostpublishedanop-edbyformerCDCDirectorTomFriedentitled,“It’stheworld’sle